Dr. Ghia on the Key Takeaways of the CAPTIVATE Study in Treatment-Naïve CLL
Paolo Ghia, MD, PhD, discusses the key takeaways of the phase 2 CAPTIVATE study in chronic lymphocytic leukemia.
Dr. Ghia on the Design of the CAPTIVATE Study in Treatment-Naïve CLL
Paolo Ghia, MD, PhD, discusses the design of the phase 2 CAPTIVATE study in treatment-naïve chronic lymphocytic leukemia.
Emerging Strategies in the Management of Relapsed/Refractory CLL
Considerations for the future treatment landscape of relapsed/refractory CLL, in light of emerging practices and clinical trial data.
Therapeutic Sequencing Strategies in Relapsed/Refractory CLL
Experts detail optimal sequencing strategies when patients with relapsed/refractory CLL move on to the next line of therapy.
Key Clinical Data in Relapsed/Refractory CLL
An in-depth analysis of current therapeutic options in relapsed/refractory chronic lymphocytic leukemia.
Frontline Therapy for CLL: Emerging Agents and Approaches
Key opinion leaders look forward to upcoming improvements in the frontline management of chronic lymphocytic leukemia.
Which Path to Take in Frontline Therapy for CLL?
Experts reflect on core decisions inherent in selecting frontline therapy for patients with CLL, specifically regarding the use of BTK inhibitors, BCL2 inhibitors, anti-CD20 agents, and chemoimmunotherapy.
Frontline Targeted Therapy in CLL: Tolerability and Toxicity Management
A comprehensive breakdown of the tolerability of frontline targeted therapies used to manage chronic lymphocytic leukemia and toxicity management.
Optimizing the Frontline Management of High-Risk CLL
After determining the parameters of high-risk CLL, key opinion leaders clarify optimal frontline management strategies.
Key Clinical Data for Frontline Targeted Therapy in CLL
Shared insight on clinical trial data for frontline targeted agents—specifically ibrutinib, acalabrutinib, and venetoclax—in chronic lymphocytic leukemia.
Global Approaches to the Frontline Management of CLL
Considering a patient’s age, as well as their deletion 17p and IgHV status, experts from around the world share their approach to the frontline management of CLL.
Frontline Therapy for Patients With CLL: Testing and Risk Classification
A review of how frontline therapy selection for patients with CLL is informed by molecular testing, staging, and risk stratification amidst a multitude of other disease factors.
Impact of Targeted Therapy in CLL
Expert insight on the impact that targeted therapies have had on the frontline treatment landscape of chronic lymphocytic leukemia.
Dr. Ghia on Key Findings From the CAPTIVATE Trial in CLL
Paolo Ghia, MD, PhD, discusses key findings from the phase 2 CAPTIVATE trial in chronic lymphocytic leukemia.
Novel Treatment Combinations in Chronic Lymphocytic Leukemia
Dr Brown and Dr Stilgenbauer provide their input on novel treatment options emerging for chronic lymphocytic leukemia.
The Future of Chronic Lymphocytic Leukemia Treatment
Dr Ghia discusses emerging treatment strategies, including some promising clinical trials in chronic lymphocytic leukemia.
Treatment Sequencing in Chronic Lymphocytic Leukemia
Experts provide an in-depth look at their approach in sequencing treatment in chronic lymphocytic leukemia.
Treatment Options in Relapsed/Refractory Chronic Lymphocytic Leukemia
Experts discuss second-line treatment options in relapsed/refractory chronic lymphocytic leukemia, including a discussion on the MURANO trial.
Chronic Lymphocytic Leukemia Treatment Considerations
Dr Brown and Dr Stilgenbauer provide advice for community-based oncologists treating chronic lymphocytic leukemia.
Role of Venetoclax in Chronic Lymphocytic Leukemia
Experts comment on the use of venetoclax-based therapy in treating chronic lymphocytic leukemia.
A Look at the ECOG 1912 and iLLUMINATE Trials
Experts Dr Stilgenbauer and Dr Ghia highlight and comment on the ECOG 1912 and iLLUMINATE trials.
A Look at the ELEVATE-TN and ASCEND Trials
Dr Stilgenbauer explains the ELEVATE-TN and ASCEND clinical trials; Dr Brown highlights the adverse effects seen with acalabrutinib.
Acalabrutinib in the Treatment of Chronic Lymphocytic Leukemia
Experts provide insight on the use of acalabrutinib in treating chronic lymphocytic leukemia.
Clinical Trials With BTK Inhibitors in Chronic Lymphocytic Leukemia
Dr Brown provides a brief overview of data available that support the use of Bruton’s tyrosine kinase inhibitors in treating chronic lymphocytic leukemia; Dr Stilgenbauer comments on mitigating and managing adverse effects in the treatment of chronic lymphocytic leukemia.
BTK Inhibitors in Treatment of Chronic Lymphocytic Leukemia
Dr Ghia provides an in-depth conversation on the use of Bruton tyrosine kinase inhibitors in treating chronic lymphocytic leukemia.
Frontline Treatment Options in Chronic Lymphocytic Leukemia
The experts comment on first-line treatment options in patients with chronic lymphocytic leukemia.
Guidelines for Chronic Lymphocytic Leukemia
Dr Brown and Dr Ghia discuss the European Society for Medical Oncology [ESMO] and International Workshop on Chronic Lymphocytic Leukemia [iwCLL] recommended guidelines in assessing and treating chronic lymphocytic leukemia.
Treatment Considerations in Newly Diagnosed CLL
Drs Stilgenbauer and Ghia provide insight on initial treatment considerations for patients with newly diagnosed chronic lymphocytic leukemia.
Dr Ganesan on the Use of ctDNA Assays For MRD Detection in Cancer Care
Dr Habib on Developments in Palliative Care For Patients With Cancer
Dr Boland on the Emergence of KRAS G12C Inhibitors in mCRC
Dr In on the Increased Incidence of Gastric Cancer in Minority Patient Populations
2 Clarke Drive Cranbury, NJ 08512